OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Quote | OKYO Pharma Limited (NASDAQ:OKYO)
Last: | $1.361 |
---|---|
Change Percent: | -2.22% |
Open: | $1.38 |
Close: | $1.361 |
High: | $1.47 |
Low: | $1.35 |
Volume: | 28,641 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | OKYO Pharma Limited (NASDAQ:OKYO)
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
Message Board Posts | OKYO Pharma Limited (NASDAQ:OKYO)
Subject | By | Source | When |
---|---|---|---|
Big volume, just needed to take a breathe | mfayman | investorshub | 10/05/2023 3:53:59 PM |
Will end up green today | Sirpeter | investorshub | 10/05/2023 3:26:10 PM |
Will be over $3 by Monday... | Sirpeter | investorshub | 10/05/2023 2:24:52 PM |
Got to add down here...could be a $75-100 | Sirpeter | investorshub | 10/05/2023 2:09:11 PM |
..thought it make $3..sell the news, terrible.. $OKYO$... | Pisd | investorshub | 10/05/2023 2:04:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...